.png)
.png)
A clinical decision made in a consulting room has a short shelf life. The adjusted dose, the blood pressure target and the instruction to return in three months all depend on what happens in the weeks that follow, and for most patients that period is invisible to the clinician who made the call. This gap between the appointment and daily life is where chronic disease management loses its grip. Vivo Care and Onpoint Healthcare Partners have completed a merger designed to close it.
Financial terms have not been disclosed. Edgemont Partners advised Vivo Care and Baird advised Onpoint. Ryan Clark becomes President and Chief Executive Officer of the combined company, with Sean Carroll as Chairman. Both firms keep their existing brand names, and current customer contracts and services continue without disruption. Buyers who have seen integrations disturb service elsewhere will notice that commitment.
Vivo Care gives the arrangement its logic. Its chronic and remote monitoring programmes have managed more than 120,000 patients, with an average retention of 18.6 months. That last figure deserves the most attention. Remote monitoring fails when patients drift away, and a provider that keeps people engaged for well over a year has solved the hardest practical problem in the field. Practices can use Vivo Care's nursing staff or their own teams on the platform, which acknowledges that workforce models differ from one organisation to the next.
Onpoint supplies the clinic side. Its artificial intelligence, working alongside human medical reviewers, reduces post-visit administrative work for more than 2,000 providers across over 35 specialties. A validation study published in June 2026 at a New Mexico health centre recorded an 84 per cent reduction in note sign-off times, while billing delays fell from 4.4 days to 2.7. These results come from a single site and should be read that way. They point in a consistent direction all the same, and they free clinician time that the monitoring model can then draw on.
The two halves meet in Point-of-Care Enrollment, now available within athenahealth and eClinicalWorks. Doctors are prompted to raise remote monitoring during the examination itself. The companies report that patient participation is 40 per cent higher than with standard follow-up outreach. The mechanism is easy to understand. A recommendation from a trusted clinician in the room carries more weight than a letter or a call days later. Clinical oversight remains with the patient's primary care team, and that design choice is what makes the model credible to doctors who are wary of outsourced care.
The transaction sits in the American market, tied to American record systems and reimbursement, and the NHS cannot import it. The relevance for Britain is structural. The 10 Year Health Plan commits the service to moving care from hospital to community and from analogue to digital. Waiting lists are still counted in millions, and general practice and community teams are stretched. Home blood pressure monitoring and virtual wards are established ideas in England, and NHS England has encouraged ambient voice technology to cut documentation time. What the Vivo Care and Onpoint combination shows is how those pieces behave when they are joined in a single workflow.
Three lessons follow for NHS leaders. Enrolment is decided in the room, so monitoring has to be embedded in the record system clinicians already use. That is harder in England, where trusts run a fragmented set of electronic patient records, and procurement frameworks do not yet reward integration of this kind. Vendors should also be asked for retention data as well as enrolment numbers, because a programme that patients abandon after three months adds work without adding safety. Any UK equivalent would need to satisfy UK GDPR, NHS clinical safety standards and the Data Security and Protection Toolkit, which is demanding but achievable for a serious supplier.
Policymakers face a question that the American deal answers only partly. Remote monitoring needs a funding route that pays for the nurse hours behind the data. Without one, devices are distributed and readings go unreviewed. Health-tech businesses in the UK should read the Vivo Care record as a benchmark, since it sets a standard for what commissioners will reasonably expect. Patients gain most when monitoring is offered by their own clinician, in person, with a clear route to someone who will act on the numbers.
Vivo Care has shown that patients stay with monitoring for well over a year when it is run properly. The NHS has the policy ambition. What remains to be settled is who pays for the infrastructure, and who is accountable when a reading at home goes unanswered.